JOURNAL ARTICLE

Replimune's Skin Cancer Drug Receives Second FDA Rejection.

  • Published In: Bloomberg.com, 2026. P. N.PAG 1 of 3

  • Database: Business Source Ultimate 2 of 3

  • Authored By: Smith, Gerry 3 of 3

Abstract

The article focuses on the U.S. Food and Drug Administration's (FDA) second denial of Replimune Group Inc.'s skin cancer treatment for advanced melanoma, which combines the company's immunotherapy with another cancer drug. The FDA cited insufficient evidence of effectiveness, specifically criticizing the reliance on a single-arm clinical trial without a control group, and stated that an adequate, well-controlled trial is required for approval. This decision reflects the FDA's stringent approach to drug reviews amid growing concerns over recent drug rejections. Melanoma, the most serious form of skin cancer, has rising global incidence and mortality rates, underscoring the significance of effective treatments. [Extracted from the article]

Additional Information

  • Source:Bloomberg.com. 2026/04, pN.PAG
  • Document Type:Article
  • Subject Area:Science
  • Publication Date:2026
  • Accession Number:192931457
  • Copyright Statement:Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.